Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by a selective loss of dopaminergic neurons in the substantia nigra (SN). It has been suggested that microglial inflammation augments the progression of PD. Neuromelanin (NM), a complex polymer pigment found in catecholaminergic neurons, has sparked interest because of the suggestion that NM is involved in cell death in Parkinson's disease, possibly via microglia activation. To further investigate the possible role of NM in the pathogenesis of PD, we conducted in vivo experiments to find out whether microglial cells become activated after injection of human neuromelanin (NM) into (1) the cerebral cortex or (2) the substantia nigra to monitor in this PD-relevant model both microglial activation and possible neurodegeneration. In this study, adult male Wistar rats received an intracerebral injection of either NM, bacterial lipopolysaccharide (LPS, positive control), phosphate-buffered saline (PBS, negative control) or colloidal gold suspension (negative particular control). After different survival times (1, 8 or 12 weeks), brain slices from the cerebral cortex or substantia nigra (SN, 1 week) were stained with Iba-1 and/or GFAP antibody to monitor microglial and astrocytic reaction, and with tyrosine hydroxylase (TH) to monitor dopaminergic cell survival (SN group only). The injection of LPS induced a strong inflammatory response in the cortex as well in the substantia nigra. Similar results could be obtained after NM injection, while the injection of PBS or gold suspension showed only moderate or no glial activation. However, the inflammatory response declined during the time course. In the SN group, there was, apart from strong microglia activation, a significant dopaminergic cell loss after 1 week of survival time. Our findings clearly indicate that extracellular NM could be one of the key molecules leading to microglial activation and neuronal cell death in the substantia nigra. This may be highly relevant to the elucidation of therapeutic strategies in PD.
Zecca
Luigi
L
Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090, Segrate-Milan, Italy.
Wilms
Henrik
H
Geick
Sebastian
S
Claasen
Jan-Hendrik
JH
Brandenburg
Lars-Ove
LO
Holzknecht
Christian
C
Panizza
Michele L
ML
Zucca
Fabio A
FA
Deuschl
Günther
G
Sievers
Jobst
J
Lucius
Ralph
R
D000818:Animals; D016923:Cell Death; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D008297:Male; D008543:Melanins / Q000276:immunology*; D017628:Microglia / Q000276:immunology*; D009410:Nerve Degeneration / Q000276:immunology / Q000473:pathology*; D009474:Neurons / Q000473:pathology; D020734:Parkinsonian Disorders / Q000276:immunology / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000276:immunology / Q000473:pathology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D008543:Melanins; C014121:neuromelanin; D014446:Tyrosine 3-Monooxygenase